Radiofrequency ablation (RFA)[a] is a medical procedure in which part of the electrical conduction system of the heart, tumor or other dysfunctional tissue is ablated using the heat generated from medium frequency alternating current (in the range of 350–500 kHz). RFA is generally conducted in the outpatient setting, using either local anesthetics or conscious sedation anesthesia. When it is delivered via catheter, it is called radiofrequency catheter ablation.
Tissue ablation using radiofrequency.
|ICD-9-CM||01.32, 04.2, 37.33, 37.34, 60.97|
Two important advantages of radio frequency current (over previously used low frequency AC or pulses of DC) are that it does not directly stimulate nerves or heart muscle and therefore can often be used without the need for general anesthetic, and that it is very specific for treating the desired tissue without significant collateral damage.
Documented benefits have led to RFA becoming widely used during the 21st century. RFA procedures are performed under image guidance (such as X-ray screening, CT scan or ultrasound) by an interventional pain specialist (such as an anesthesiologist), interventional radiologist, otolaryngologists, a gastrointestinal or surgical endoscopist, or a cardiac electrophysiologist, a subspecialty of cardiologists.
RFA may be performed to treat tumors in the lung, liver, kidney, and bone, as well as other body organs less commonly. Once the diagnosis of tumor is confirmed, a needle-like RFA probe is placed inside the tumor. The radiofrequency waves passing through the probe increase the temperature within tumor tissue and results in destruction of the tumor. RFA can be used with small tumors, whether these arose within the organ (primary tumors) or spread to the organ (metastases). The suitability of RFA for a particular tumor depends on multiple factors.
RFA can usually be administered as an outpatient procedure, though may at times require a brief hospital stay. RFA may be combined with locally delivered chemotherapy to treat hepatocellular carcinoma (primary liver cancer). A method currently in phase III trials uses the low-level heat (hyperthermia) created by the RFA probe to trigger release of concentrated chemotherapeutic drugs from heat-sensitive liposomes in the margins around the ablated tissue as a treatment for Hepatocellular carcinoma (HCC). Radiofrequency ablation is also used in pancreatic cancer and bile duct cancer.
RFA has become increasingly important in the care of benign bone tumors, most notably osteoid osteomas. Since the procedure was first introduced for the treatment of osteoid osteomas in the 1990s, it has been shown in numerous studies to be less invasive and expensive, to result in less bone destruction and to have equivalent safety and efficacy to surgical techniques, with 66 to 95% of people reporting freedom from symptoms. While initial success rates with RFA are high, symptom recurrence after RFA treatment has been reported, with some studies demonstrating a recurrence rate similar to that of surgical treatment. RFA is also increasingly used in the palliative treatment of painful metastatic bone disease in people who are not eligible or do not respond to traditional therapies ( i.e. radiation therapy, chemotherapy, palliative surgery, bisphosphonates or analgesic medications).
Radiofrequency energy is used in heart tissue or normal parts to destroy abnormal electrical pathways that are contributing to a cardiac arrhythmia. It is used in recurrent atrial flutter (Afl), atrial fibrillation (AF), supraventricular tachycardia (SVT), atrial tachycardia, Multifocal Atrial Tachycardia (MAT) and some types of ventricular arrhythmia. The energy-emitting probe (electrode) is at the tip of a catheter which is placed into the heart, usually through a vein. This catheter is called the ablator. The practitioner first "maps" an area of the heart to locate the abnormal electrical activity (electrophysiology study) before the responsible tissue is eliminated. Ablation is now the standard treatment for SVT and typical atrial flutter and the technique can also be used in AF, either to block the atrioventricular node after implantation of a pacemaker or to block conduction within the left atrium, especially around the pulmonary veins. In some conditions, especially forms of intra-nodal re-entry (the most common type of SVT), also called atrioventricular nodal reentrant tachycardia or AVNRT, ablation can also be accomplished by cryoablation (tissue freezing using a coolant which flows through the catheter) which avoids the risk of complete heart block – a potential complication of radiofrequency ablation in this condition. Recurrence rates with cryoablation are higher, though. Microwave ablation, where tissue is ablated by the microwave energy "cooking" the adjacent tissue, and ultrasonic ablation, creating a heating effect by mechanical vibration, or laser ablation have also been developed but are not in widespread use.
A new and promising indication for the use of radiofrequency technology has made news in the last few years. Hypertension is a very common condition, with about 1 billion people over the world, nearly 75 million in the US alone. Complications of inadequately controlled hypertension are many and have both individual and global impact. Treatment options include medications, diet, exercise, weight reduction and meditation. Inhibition of the neural impulses that are believed to cause or worsen hypertension has been tried for a few decades. Surgical sympathectomy has helped but not without significant side effects. Therefore, the introduction of non-surgical means of renal denervation with radiofrequency ablation catheter was enthusiastically welcomed. Although, the initial use of radiofrequency-generated heat to ablate nerve endings in the renal arteries to aid in management of 'resistant hypertension' were encouraging, the most recent phase 3 studying looking at catheter-based renal denervation for the treatment of resistant hypertension failed to show any significant reduction in systolic blood pressure.
Radiofrequency ablation is a dermatosurgical procedure by using various forms of alternating current. Types of radiofrequency are electrosection, electrocoagulation, electrodessication and fulguration. The use of radiofrequency ablation has obtained importance as it can be used to treat most of the skin lesions with minimal side effects and complications.
Radiofrequency ablation is a minimally invasive procedure used in the treatment of varicose veins. It is an alternative to the traditional stripping operation. Under ultrasound guidance, a radiofrequency catheter is inserted into the abnormal vein and the vessel treated with radio-energy, resulting in closure of the involved vein. Radiofrequency ablation is used to treat the great saphenous vein, the small saphenous vein, and the perforator veins. The latter are connecting veins that transport blood from the superficial veins to the deep veins. Branch varicose veins are then usually treated with other minimally invasive procedures, such as ambulatory phlebectomy, sclerotherapy, or foam sclerotherapy. Currently, the VNUS ClosureRFS stylet is the only device specifically cleared by FDA for endovenous ablation of perforator veins.
It should be pointed out that the possibility of skin burn during the procedure is very small, because the large volumes (500 cc) of dilute Lidocaine (0.1%) tumescent anesthesia injected along the entire vein prior to the application of radiofrequency provide a heat sink that absorbs the heat created by the device. Early studies have shown a high success rate with low rates of complications.
Obstructive sleep apneaEdit
RFA was first studied in obstructive sleep apnea (OSA) in a pig model. RFA has been recognized as a somnoplasty treatment option in selected situations by the American Academy of Otolaryngology but was not endorsed for general use in the American College of Physicians guidelines.
The clinical application of RFA in obstructive sleep apnea is reviewed in that main article, including controversies and potential advantages in selected medical situations. Unlike other electrosurgical devices, RFA allows very specific treatment targeting of the desired tissue with a precise line of demarcation that avoids collateral damage, which is crucial in the head and neck region due to its high density of major nerves and blood vessels. RFA also does not require high temperatures. However, overheating from misapplication of RFA can cause harmful effects such as coagulation on the surface of the electrode, boiling within tissue that can leave "a gaping hole", tears, or even charring.
RFA, or rhizotomy, is sometimes used to treat severe chronic pain in the lower (lumbar) back, where radio frequency waves are used to produce heat on specifically identified nerves surrounding the facet joints on either side of the lumbar spine. By generating heat around the nerve, the nerve gets ablated thus destroying its ability to transmit signals to the brain. The nerves to be ablated are identified through injections of local anesthesia (such as lidocaine) prior to the RFA procedure. If the local anesthesia injections provide temporary pain relief, then RFA is performed on the nerve(s) that responded well to the injections. RFA is a minimally invasive procedure which can usually be done in day-surgery clinics, going home shortly after completion of the procedure. The person is awake during the procedure, so risks associated with general anesthesia are avoided. An intravenous line may be inserted so that mild sedatives can be administered.
In April 2017, the US Food and Drug Administration approved a commercial device using cooled radiofrequency ablation, with effects lasting for up to a year of pain relief from knee arthritis. A review of preliminary clinical research indicated that better efficacy of ablation for knee pain was achieved by targeting the genicular nerve (one of the articular branches of the tibial nerve), targeting larger nerves including the femoral nerve, or by using an intra-articular procedure.
Whether for back or knee pain, a drawback for this procedure is that nerves recover function over time, so the pain relief achieved lasts only temporarily (3–15 months) in most people.
Radiofrequency ablation has been shown to be a safe and effective treatment for Barrett's esophagus. The balloon-based radiofrequency procedure was invented by Robert A. Ganz, Roger Stern and Brian Zelickson in 1999 (System and Method for Treating Abnormal Tissue in the Human Esophagus). While the person is sedated, a catheter is inserted into the esophagus and radiofrequency energy is delivered to the diseased tissue. This outpatient procedure typically lasts from fifteen to thirty minutes. Two months after the procedure, the physician performs an upper endoscopic examination to assess the esophagus for residual Barrett's esophagus. If any Barrett's esophagus is found, the disease can be treated with a focal RFA device. Between 80–90% or greater of people in numerous clinical trials have shown complete eradication of Barrett's esophagus in approximately two to three treatments with a favorable safety profile. The treatment of Barrett's esophagus by RFA is durable for up to 5 years.
RFA is also used in radiofrequency lesioning, for vein closure in areas where intrusive surgery is contraindicated by trauma, and in liver resection to control bleeding (hemostasis) and facilitate the transection process.
This process has also been used with success to treat TRAP sequence in multiple gestation pregnancies. This is becoming the leading method of treatment with a higher success rate for saving the 'pump' twin in recent studies than previous methods including laser photocoagulation. Due to the rarity of this complication, its correct diagnosis statistics are not yet reliable.
RFA is used to treat uterine fibroids using the heat energy of radio frequency waves to ablate the fibroid tissue. The Acessa device obtained FDA approval in 2012 and is now on third-generation technology, the Acessa ProVu. The device is inserted via a laparoscopic probe and guided inside the fibroid tissue using an ultrasound probe. The heat shrinks the fibroids. Clinical data on the procedure shows an average of 45% shrinkage.
- "Fulguration: NCI Dictionary of Cancer Terms". National Cancer Institute. 2011-02-02. Retrieved 10 May 2018.
- Courtney M. Townsend (2012). Sabiston textbook of surgery : the biological basis of modern surgical practice (19th ed.). Philadelphia, PA: Elsevier Saunders. p. 236. ISBN 978-1-4377-1560-6.
- "Ablation for Arrhythmias". American Heart Association. 2017.
- "Radiofrequency ablation for cancer". Mayo Clinic. 2017.
- Dunn, Lauren and Gussone, Felix (13 June 2017). "'Cool' New Knee Procedure Eases Arthritis Pain Without Surgery". NBC News, New York. Retrieved 13 June 2017.CS1 maint: multiple names: authors list (link)
- Ambrogi MC, Fanucchi O, Cioni R, Dini P, De Liperi A, Cappelli C, Davini F, Bartolozzi C, Mussi A (2011). "Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study". J Thorac Oncol. 6 (12): 2044–51. doi:10.1097/JTO.0b013e31822d538d. PMID 22052222.
- NHS, June 2008 - Radiofrequency ablation for lung cancer
- Daily Telegraph - June 2008 - Lung cancer radiation treatment offers new hope
- BBC News- 16 January 2009 - Liver tumours 'microwaved away'
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
- Hadjicostas, P.; Malakounides, N.; Varianos, C.; Kitiris, E.; Lerni, F.; Symeonides, P. (2006). "Radiofrequency ablation in pancreatic cancer". HPB. 8 (1): 61–64. doi:10.1080/13651820500466673. PMC 2131369. PMID 18333241.
- Rosenthal, D I; Alexander, A; Rosenberg, A E; Springfield, D (1992-04-01). "Ablation of osteoid osteomas with a percutaneously placed electrode: a new procedure". Radiology. 183 (1): 29–33. doi:10.1148/radiology.183.1.1549690. ISSN 0033-8419. PMID 1549690.
- Weber, Marc-André; Sprengel, Simon David; Omlor, Georg W.; Lehner, Burkhard; Wiedenhöfer, Bernd; Kauczor, Hans-Ulrich; Rehnitz, Christoph (2015-04-25). "Clinical long-term outcome, technical success, and cost analysis of radiofrequency ablation for the treatment of osteoblastomas and spinal osteoid osteomas in comparison to open surgical resection". Skeletal Radiology. 44 (7): 981–93. doi:10.1007/s00256-015-2139-z. ISSN 0364-2348. PMID 25910709.
- Rosenthal, Daniel I.; Hornicek, Francis J.; Torriani, Martin; Gebhardt, Mark C.; Mankin, Henry J. (2003-10-01). "Osteoid Osteoma: Percutaneous Treatment with Radiofrequency Energy". Radiology. 229 (1): 171–75. doi:10.1148/radiol.2291021053. ISSN 0033-8419. PMID 12944597.
- Rimondi, Eugenio; Mavrogenis, Andreas F.; Rossi, Giuseppe; Ciminari, Rosanna; Malaguti, Cristina; Tranfaglia, Cristina; Vanel, Daniel; Ruggieri, Pietro (2011-08-14). "Radiofrequency ablation for non-spinal osteoid osteomas in 557 patients". European Radiology. 22 (1): 181–88. doi:10.1007/s00330-011-2240-1. ISSN 0938-7994. PMID 21842430.
- Rosenthal, Daniel I.; Hornicek, Francis J.; Wolfe, Michael W.; Jennings, L. Candace; Gebhardt, Mark C.; Mankin, Henry J. (1998-06-01). "Percutaneous Radiofrequency Coagulation of Osteoid Osteoma Compared with Operative Treatment*". J Bone Joint Surg Am. 80 (6): 815–21. CiteSeerX 10.1.1.1018.5024. doi:10.2106/00004623-199806000-00005. ISSN 0021-9355. PMID 9655099.
- Dupuy, Damian E.; Liu, Dawei; Hartfeil, Donna; Hanna, Lucy; Blume, Jeffrey D.; Ahrar, Kamran; Lopez, Robert; Safran, Howard; DiPetrillo, Thomas (2010-02-15). "Percutaneous radiofrequency ablation of painful osseous metastases". Cancer. 116 (4): 989–97. doi:10.1002/cncr.24837. ISSN 1097-0142. PMC 2819592. PMID 20041484.
- Deisenhofer I, Zrenner B, Yin YH, et al. (2010). "Cryoablation Versus Radiofrequency Energy for the Ablation of Atrioventricular Nodal Reentrant Tachycardia (the CYRANO Study) : Results From a Large Multicenter Prospective Randomized Trial". Circulation. 122 (22): 2239–45. doi:10.1161/circulationaha.110.970350. PMID 21098435.
- Bhatt DL, Kandzari KE, O'Neill WW, et al. (2014). "A Controlled Trial of Renal Denervation for Resistant Hypertension (SYMPLICITY HTN-3 Trial)". N Engl J Med. 370 (15): 1393–401. doi:10.1056/NEJMoa1402670. PMID 24678939.
- Loesch MM, Somani AK, Kingsley MM, Travers JB, Spandau DF (2014). "Skin resurfacing procedures: new and emerging options". Clin Cosmet Investig Dermatol. 7: 231–41. doi:10.2147/CCID.S50367. PMC 4155739. PMID 25210469.
- Endovenous ablation of perforator veins
- Avery J, Kumar K, Thakur V, Thakur A (2014). "Radiofrequency ablation as first-line treatment of varicose veins". Am Surg. 80 (3): 231–35. PMID 24666862.
- "Submucosal Ablation of the Tongue Base for OSAS". American Academy of Otolaryngology – Head and Neck Surgery. Retrieved 29 October 2013.
- Qaseem, A; Holty, JE; Owens, DK; Dallas, P; Starkey, M; Shekelle, P; for the Clinical Guidelines Committee of the American College of, Physicians (Sep 24, 2013). "Management of Obstructive Sleep Apnea in Adults: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 159 (7): 471–83. doi:10.7326/0003-4819-159-7-201310010-00704. PMID 24061345.
- Bashetty, Kusum; Gururaj Nadig Sandhya Kapoor (19 November 2009). "Electrosurgery in aesthetic and restorative dentistry: A literature review and case reports". Journal of Conservative Dentistry. 12 (4): 139–44. doi:10.4103/0972-0707.58332. PMC 2879725. PMID 20543922.
- Eick, Olaf J (1 July 2002). "Temperature Controlled Radiofrequency Ablation". Indian Pacing Electrophysiol. 3. 2 (3): 66–73. PMC 1564057. PMID 17006561.
- Jessup, Cynthia (21 April 2017). "FDA Green Lights Halyard Health's Coolief for the Management of Osteoarthritis Knee Pain". FDAnews, Falls Church, VA. Retrieved 13 June 2017.
- Gupta, A; Huettner, D. P; Dukewich, M (2017). "Comparative Effectiveness Review of Cooled Versus Pulsed Radiofrequency Ablation for the Treatment of Knee Osteoarthritis: A Systematic Review". Pain Physician. 20 (3): 155–171. PMID 28339430.
- Ganz R, Utley D, Stern R, et al. (2004). "Complete Ablation of Esophageal Epithelium Using a Balloon-based Bipolar Electrode". Gastrointestinal Endoscopy. 60 (6): 1002–10. doi:10.1016/s0016-5107(04)02220-5. PMID 15605025.
- Fleischer DE, Overholt BF, Sharma VK, et al. (2010). "Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial". Endoscopy. 42 (10): 781–89. doi:10.1055/s-0030-1255779. PMID 20857372.
- Shaheen NJ, Sharma P, Overholt BF, et al. (2009). "Radiofrequency Ablation in Barrett's Esophagus with Dysplasia". New England Journal of Medicine. 360 (22): 2277–88. doi:10.1056/NEJMoa0808145. PMID 19474425.
- Shaheen NJ, Overholt BF, Sampliner RE, et al. (2011). "Durability of Ablation in Barrett's Esophagus with Dysplasia". Gastroenterology. 141 (2): 460–68. doi:10.1053/j.gastro.2011.04.061. PMC 3152658. PMID 21679712.
- Van Vilsteren FG, Pouw RE, Seewald S, et al. (June 2011). "Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high grade dysplasia or early cancer: a multicentre randomised trial". Gut. 60 (6): 765–73. doi:10.1136/gut.2010.229310. PMID 21209124.
- "Acessa Health Procedure".
- King, Paula (10 December 2012). "Brentwood medical company obtains FDA approval for new medical device". San Jose, CA: The Mercury News, Digital First Media.
- Chuter GS, Chua YP, Connell DA, Blackney MC (Jan 2013). "Ultrasound-guided radiofrequency ablation in the management of interdigital (Morton's) neuroma". Skeletal Radiol. 42 (1): 107–11. doi:10.1007/s00256-012-1527-x. PMID 23073898.
- Gurdezi S, White T, Ramesh P (2013). "Alcohol injection for Morton's neuroma: a five-year follow-up". Foot Ankle Int. 34 (8): 1064–67. doi:10.1177/1071100713489555. PMID 23669161.